From: Validation of a guideline-based composite outcome assessment tool for asthma control
 | β2 use | PEF | N-T awake | Exac. | EV | AE |
---|---|---|---|---|---|---|
Well controlled | Â | Â | Â | Â | Â | Â |
Symptoms | 0.52 | 0.23 | 0.37 | 0.13 | 0.13 | 0.05 |
β2 use |  | 0.28 | 0.46 | 0.13 | 0.11 | 0.03 |
PEF | Â | Â | 0.24 | 0.10 | 0.08 | 0.04 |
N-T awake | Â | Â | Â | 0.12 | 0.09 | 0.04 |
Exac. | Â | Â | Â | Â | 0.49 | 0.13 |
EV | Â | Â | Â | Â | Â | 0.18 |
Totally controlled | Â | Â | Â | Â | Â | Â |
Symptoms | 0.68 | 0.25 | 0.38 | 0.09 | 0.08 | 0.01 |
β2 use |  | 0.26 | 0.45 | 0.10 | 0.09 | 0.01 |
PEF | Â | Â | 0.24 | 0.10 | 0.08 | 0.04 |
N-T awake | Â | Â | Â | 0.12 | 0.09 | 0.04 |
Exac. | Â | Â | Â | Â | 0.49 | 0.13 |
EV | Â | Â | Â | Â | Â | 0.18 |